Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
NewAmsterdam Pharma
Study ID
NCT06496243
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Dyslipidemias

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The goal of this open label 16 week trial is to evaluate Lp(a) levels for patients with elevated Lp(a) being treated with obicetrapib and obiceptrapib/evolocumab Patients will: Have baseline Lp(a) tested at randomization Take 10mg/dL obiceptrapib daily for 8 weeks and have Lp(a) tested at Week 8 Take 10 mg/dL obicetrapib daily/evolocumab 140 every other week for 8 weeks and have Lp(a) retested at Week 16

Key Dates

Start date
Dec 2, 2024
Status verified
Apr 2026
Primary completion
Nov 30, 2026
Completion
Feb 28, 2027

Study Design

Enrollment
69 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: obicetrapib/evolocumab combination
    obicetrapib 10 mg/dL daily for 8 weeks followed by obicetrapib 10 mg/dL daily + evolocumab 140 mg/dL every other week for 8 weeks

Primary Outcome Measure

To evaluate the effect of evolocumab in combination with obicetrapib on lipoprotein (a) (Lp[a]). [ Time Frame: 16 weeks from baseline; 8 weeks on combination therapy ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UPennPhiladelphiaPennsylvania19104
Archna Bajaj (PRINCIPAL_INVESTIGATOR)

Find similar trials in Philadelphia, PA

By research site
UPenn· Philadelphia, PA

Related Studies